Andrew Weickhardt

8.2k total citations · 2 hit papers
111 papers, 3.4k citations indexed

About

Andrew Weickhardt is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Andrew Weickhardt has authored 111 papers receiving a total of 3.4k indexed citations (citations by other indexed papers that have themselves been cited), including 68 papers in Pulmonary and Respiratory Medicine, 64 papers in Oncology and 27 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Andrew Weickhardt's work include Prostate Cancer Treatment and Research (28 papers), Lung Cancer Treatments and Mutations (22 papers) and Cancer Immunotherapy and Biomarkers (21 papers). Andrew Weickhardt is often cited by papers focused on Prostate Cancer Treatment and Research (28 papers), Lung Cancer Treatments and Mutations (22 papers) and Cancer Immunotherapy and Biomarkers (21 papers). Andrew Weickhardt collaborates with scholars based in Australia, United States and United Kingdom. Andrew Weickhardt's co-authors include D. Ross Camidge, Robert C. Doebele, Dara L. Aisner, Wilbur A. Franklin, Marileila Varella‐Garcia, Anh T. Le, Xian Lu, Laurie E. Gaspar, Benjamin Scheier and Gregory N. Gan and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Andrew Weickhardt

104 papers receiving 3.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Mechanisms of Resistance to Crizotinib in Patients with ALK Gene Rearranged Non–Small Cell Lung Cancer

2012 820 citations Robert C. Doebele, Amanda Pilling et al. Clinical Cancer Research profile →
Local Ablative Therapy of Oligoprogressive Disease Prolongs Disease Control by Tyrosine Kinase Inhibitors in Oncogene-Addicted Non–Small-Cell Lung Cancer

2012 508 citations Andrew Weickhardt, Xian Lu et al. Journal of Thoracic Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Andrew Weickhardt Australia	23	2.3k	2.3k	967	527	393	111	3.4k
Hong‐Hong Yan China	31	2.8k 1.2×	2.5k 1.1×	870 0.9×	866 1.6×	197 0.5×	133	3.7k
Venice Archer United Kingdom	9	3.6k 1.5×	3.6k 1.5×	919 1.0×	663 1.3×	214 0.5×	16	4.6k
V.A. Miller United States	22	1.6k 0.7×	2.1k 0.9×	924 1.0×	508 1.0×	350 0.9×	83	3.0k
Davey B. Daniel United States	19	2.1k 0.9×	2.2k 1.0×	538 0.6×	688 1.3×	237 0.6×	82	3.3k
David A. Ramies United States	18	2.9k 1.2×	2.7k 1.2×	1.2k 1.2×	608 1.2×	316 0.8×	37	3.8k
N. Moore Switzerland	16	2.6k 1.1×	2.0k 0.9×	1.7k 1.8×	1.2k 2.3×	235 0.6×	27	4.0k
Mauro Zukin Brazil	13	2.8k 1.2×	2.4k 1.0×	748 0.8×	519 1.0×	158 0.4×	38	3.5k
Jin‐Ji Yang China	36	3.9k 1.7×	3.5k 1.5×	1.2k 1.2×	1.1k 2.0×	295 0.8×	146	4.9k
Jose R. Pereira Germany	8	3.5k 1.5×	3.2k 1.4×	866 0.9×	501 1.0×	151 0.4×	8	4.3k
Oleg Gladkov Russia	18	2.3k 1.0×	1.8k 0.8×	1.8k 1.9×	1.1k 2.1×	193 0.5×	65	3.7k

Countries citing papers authored by Andrew Weickhardt

Since Specialization

Citations

This map shows the geographic impact of Andrew Weickhardt's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andrew Weickhardt with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andrew Weickhardt more than expected).

Fields of papers citing papers by Andrew Weickhardt

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Andrew Weickhardt. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andrew Weickhardt. The network helps show where Andrew Weickhardt may publish in the future.

Co-authorship network of co-authors of Andrew Weickhardt

This figure shows the co-authorship network connecting the top 25 collaborators of Andrew Weickhardt. A scholar is included among the top collaborators of Andrew Weickhardt based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Andrew Weickhardt. Andrew Weickhardt is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Hansen, Aaron R., Alison Yan Zhang, Valentina Boni, et al.. (2025). A multicenter, open-label phase 1/2 study of TYRA-300 in advanced urothelial carcinoma and other solid tumors with activating FGFR3 alterations (SURF301).. Journal of Clinical Oncology. 43(5_suppl).

Williams, Colin C., Wei Hong, A. Antón, et al.. (2025). Treatment patterns and outcomes for younger patients with metastatic castration-resistant prostate cancer (mCRPC); An Australian prospective registry study. Clinical Genitourinary Cancer. 23(3). 102345–102345. 1 indexed citations

Choi, Sharon, Roxanne Quinn, Eddy Saad, et al.. (2024). Efficacy of post-lenvatinib treatments in patients (pts) with advanced renal cell carcinoma (aRCC).. Journal of Clinical Oncology. 42(16_suppl). 4538–4538. 2 indexed citations

Azad, Arun, Mathias Bressel, Hsiang Tan, et al.. (2024). LBA66 UpFrontPSMA: A randomised phase II study of sequential 177Lu-PSMA-617 and docetaxel (D) versus docetaxel in metastatic hormone-sensitive prostate cancer (mHSPC). Annals of Oncology. 35. S1255–S1256. 1 indexed citations

Wyant, Timothy, Drew Rasco, Andrew Haydon, et al.. (2024). 464 (PB452): Determination of the phase 2 dose of AU-007, an AI-designed human monoclonal antibody that redirects IL-2 to T-effector cells. European Journal of Cancer. 211. 114971–114971.

Hansen, Aaron R., Charlene Mantia, Andrew Weickhardt, et al.. (2024). 72 (PB060): TYRA-300, an oral, FGFR3-selective inhibitor: Preliminary pharmacokinetic and pharmacodynamic analysis from SURF301, the multicenter open-label phase 1/2 study of TYRA-300 in advanced urothelial carcinoma and other solid tumors with activating FGFR3 alterations. European Journal of Cancer. 211. 114599–114599.

Tremblay, Samuel, Andrew Weickhardt, Ian D. Davis, et al.. (2023). Influence of molecular imaging on patient selection for treatment intensification prior to salvage radiation therapy for prostate cancer: a post hoc analysis of the PROPS trial. Cancer Imaging. 23(1). 57–57. 1 indexed citations

Lewin, Jeremy, Andrew Weickhardt, James Lynam, et al.. (2023). Patterns of Relapse in Australian Patients With Clinical Stage 1 Testicular Cancer: Utility of the Australian and New Zealand Urogenital and Prostate Cancer Trials Group Surveillance Recommendations. JCO Oncology Practice. 19(11). 973–980. 3 indexed citations

Emmett, Louise, Shalini Subramaniam, Megan Crumbaker, et al.. (2023). LBA84 Enzalutamide and 177Lu-PSMA-617 in poor-risk, metastatic, castration-resistant prostate cancer (mCRPC): A randomised, phase II trial: ENZA-p (ANZUP 1901). Annals of Oncology. 34. S1325–S1325. 7 indexed citations

10.

Balasubramanian, Adithya, Ashray Gunjur, Andrew Weickhardt, et al.. (2022). Adjuvant therapies for non-muscle-invasive bladder cancer: advances during BCG shortage. World Journal of Urology. 40(5). 1111–1124. 29 indexed citations

11.

Luk, Ian Y., Laura J. Jenkins, Andrew Martin, et al.. (2021). Rapid Resistance of FGFR-driven Gastric Cancers to Regorafenib and Targeted FGFR Inhibitors can be Overcome by Parallel Inhibition of MEK. Molecular Cancer Therapeutics. 20(4). 704–715. 14 indexed citations

12.

Shenderov, Eugene, Piotr J. Wysocki, Wen Xu, et al.. (2021). 620P MGC018, an anti-B7-H3 antibody-drug conjugate (ADC), in patients with advanced solid tumors: Preliminary results of phase I cohort expansion. Annals of Oncology. 32. S657–S659. 21 indexed citations

13.

Antón, A., Shirley Wong, Andrew Weickhardt, et al.. (2021). Real-world incidence of symptomatic skeletal events and bone-modifying agent use in castration-resistant prostate cancer – an Australian multi-centre observational study. European Journal of Cancer. 157. 485–492. 8 indexed citations

14.

Jensen, Allan, Jeremy Shapiro, Andrew Weickhardt, et al.. (2020). 226P Use of PSMA PET in metastatic castration-resistant prostate cancer (mCRPC). Annals of Oncology. 31. S1329–S1330. 1 indexed citations

15.

Metser, Ur, Sue Chua, Bao Ho, et al.. (2019). The Contribution of Multiparametric Pelvic and Whole-Body MRI to Interpretation of ¹⁸F-Fluoromethylcholine or ⁶⁸Ga-HBED-CC PSMA-11 PET/CT in Patients with Biochemical Failure After Radical Prostatectomy. Journal of Nuclear Medicine. 60(9). 1253–1258. 22 indexed citations

16.

Hamid, Anis, et al.. (2018). Communicating prognosis of patients with advanced cancer between health care providers: a tertiary cancer center review of written correspondence. Annals of Palliative Medicine. 7(4). 404–410. 4 indexed citations

17.

Ha, F., Andrew Weickhardt, Sagun Parakh, et al.. (2017). Survival and functional outcomes of patients with metastatic solid organ cancer admitted to the intensive care unit of a tertiary centre. Critical Care and Resuscitation. 19(2). 159–166. 10 indexed citations

18.

Weickhardt, Andrew, et al.. (2016). Survival and functional outcomes of patients with metastatic solid organ cancer admitted to the intensive care unit of a general tertiary centre. Annals of Oncology. 27. vi517–vi517. 2 indexed citations

19.

Doebele, Robert C., Amanda Pilling, Dara L. Aisner, et al.. (2012). Mechanisms of Resistance to Crizotinib in Patients with ALK Gene Rearranged Non–Small Cell Lung Cancer. Clinical Cancer Research. 18(5). 1472–1482. 820 indexed citations breakdown →

20.

Weickhardt, Andrew, Robert C. Doebele, Ana B. Oton, et al.. (2012). A Phase I/II Study of Erlotinib in Combination with the Anti-Insulin-Like Growth Factor-1 Receptor Monoclonal Antibody IMC-A12 (Cixutumumab) in Patients with Advanced Non-small Cell Lung Cancer. Journal of Thoracic Oncology. 7(2). 419–426. 46 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact